- Email: [email protected]
Thursday, March 29
THURSDAY, MARCH 29
8:00 –12:00 pm Featured Symposium Accidents Will Happen: Cases Gone Awry Room: 132/133 Moderator/Coordinator: Robert K.W. Ryu, MD, FSIR
This symposium is a case-based review of IR complications, ranging from the mundane to the absurd. At the end of this session, the learner should be able to: 1. Describe IR cases that resulted in complications 2. Develop strategies to avoid complications 3. Identify common and rare causes of complications Faculty: David W. Hunter, MD, FSIR Matthew S. Johnson, MD, FSIR Lindsay Machan, MD, FSIR Hector Ferral, MD Jeffrey A. Himmelberg, MD Luke E. Sewall, MD Sue E. Hanks, MD, FSIR Jeffrey J. Critchfield, MD Christopher A. Molvar, MD
8:00 –12:00 pm Featured Symposium IO 2012: What the Interventional Oncologist Needs to Know Room: 134/135 Moderator/Coordinator: Jeff H. Geschwind, MD, FSIR, and William S. Rilling, MD, FSIR
This symposium will provide attendees with a review of the important basics of interventional oncology including cytotoxic and new targeted chemotherapy agents, tailoring therapy based on biomarkers, managing symptoms in the IO patient, communicating with cancer patients and assessing tumor response. The second session of the symposium will focus on disease-based treatment guidelines with a review of the current status, future trends and the role of IO treatments. At the end of this session, the learner should be able to:
8:00 – 8:15 am Oncology 101—Cytotoxic Chemotherapy: Current Agents, Regimens and Toxicities David Cosgrove, MD 8:15– 8:30 am Oncology 102—Targeted Agents: Mechanisms, Indications and Toxicities Richard Finn, MD 8:30 – 8:45 am Oncology 201—Important Biomarkers and Tailoring Therapy David Cosgrove, MD 8:45–9:00 am Oncology 301—Managing Common Cancer-Related Symptoms in the IO Patient William S. Rilling, MD, FSIR 9:00 –9:15 am Oncology 401—Assessing Tumor Response in the Age of Locoregional Therapy and Targeted Agents Riad Salem, MD, MBA, FSIR 9:15–9:30 am Oncology 501—Communication with Cancer Patients and Their Families Christian Meyer, MD 9:30 –9:45 am Panel 10:00 –10:15 am Early HCC Riccardo A. Lencioni, MD 10:15–10:30AM Advanced HCC Jeff H. Geschwind, MD, FSIR 10:30 –10:45 am Colorectal Mets Michael C. Soulen, MD, FSIR 10:45–11:00 am NET Mets William S. Rilling, MD, FSIR 11:00 –11:15 am NSSC Lung Cancer Stephen B. Solomon, MD, FSIR 11:15–11:30 am Lung Mets Thierry De Baere, MD 11:30 –11:45 am Early Renal Cancer Christos Georgiades, MD, PhD, FSIR 11:45–12:00 pm Panel
THURSDAY
1. Describe the mechanisms, indications, and toxicities of targeted agents 2. List current and future important biomarkers and how they guide therapy 3. Develop an algorithm for treating common symptoms in the IO patient 4. Review the strengths and weaknesses of various imaging criteria following loco-regional therapy
5. Review current treatment guidelines and trends for the major patient populations served by IO physicians
8:00 –12:00 pm Featured Symposium Accidents Will Happen: Cases Gone Awry Room: 132/133 Moderator/Coordinator: Robert K.W. Ryu, MD, FSIR
This symposium is a case-based review of IR complications, ranging from the mundane to the absurd. At the end of this session, the learner should be able to: 1. Describe IR cases that resulted in complications 2. Develop strategies to avoid complications 3. Identify common and rare causes of complications Faculty: David W. Hunter, MD, FSIR Matthew S. Johnson, MD, FSIR Lindsay Machan, MD, FSIR Hector Ferral, MD Jeffrey A. Himmelberg, MD Luke E. Sewall, MD Sue E. Hanks, MD, FSIR Jeffrey J. Critchfield, MD Christopher A. Molvar, MD
8:00 –12:00 pm Featured Symposium IO 2012: What the Interventional Oncologist Needs to Know Room: 134/135 Moderator/Coordinator: Jeff H. Geschwind, MD, FSIR, and William S. Rilling, MD, FSIR
This symposium will provide attendees with a review of the important basics of interventional oncology including cytotoxic and new targeted chemotherapy agents, tailoring therapy based on biomarkers, managing symptoms in the IO patient, communicating with cancer patients and assessing tumor response. The second session of the symposium will focus on disease-based treatment guidelines with a review of the current status, future trends and the role of IO treatments. At the end of this session, the learner should be able to:
8:00 – 8:15 am Oncology 101—Cytotoxic Chemotherapy: Current Agents, Regimens and Toxicities David Cosgrove, MD 8:15– 8:30 am Oncology 102—Targeted Agents: Mechanisms, Indications and Toxicities Richard Finn, MD 8:30 – 8:45 am Oncology 201—Important Biomarkers and Tailoring Therapy David Cosgrove, MD 8:45–9:00 am Oncology 301—Managing Common Cancer-Related Symptoms in the IO Patient William S. Rilling, MD, FSIR 9:00 –9:15 am Oncology 401—Assessing Tumor Response in the Age of Locoregional Therapy and Targeted Agents Riad Salem, MD, MBA, FSIR 9:15–9:30 am Oncology 501—Communication with Cancer Patients and Their Families Christian Meyer, MD 9:30 –9:45 am Panel 10:00 –10:15 am Early HCC Riccardo A. Lencioni, MD 10:15–10:30AM Advanced HCC Jeff H. Geschwind, MD, FSIR 10:30 –10:45 am Colorectal Mets Michael C. Soulen, MD, FSIR 10:45–11:00 am NET Mets William S. Rilling, MD, FSIR 11:00 –11:15 am NSSC Lung Cancer Stephen B. Solomon, MD, FSIR 11:15–11:30 am Lung Mets Thierry De Baere, MD 11:30 –11:45 am Early Renal Cancer Christos Georgiades, MD, PhD, FSIR 11:45–12:00 pm Panel
THURSDAY
1. Describe the mechanisms, indications, and toxicities of targeted agents 2. List current and future important biomarkers and how they guide therapy 3. Develop an algorithm for treating common symptoms in the IO patient 4. Review the strengths and weaknesses of various imaging criteria following loco-regional therapy
5. Review current treatment guidelines and trends for the major patient populations served by IO physicians